Untitled

Fatty Acid Regulation of Oxidation and Synthesis

• Overview of Fatty Acid Regulation

  • Focus on the balance between fatty acid oxidation and synthesis (triglycerides and phospholipids).

Fatty Acyl CoA Activation

• Fatty acyl CoA

  • Activated form of fatty acids before beta-oxidation.

  • Intermediary for synthesis of triglycerides and phospholipids.

Carnitine Shuttle and Regulation

• Carnitine Acyltransferase I

  • Located at the outer surface of mitochondria, acts as a gatekeeper for fatty acid transport into the mitochondria.

  • Role in transitioning fatty acyl CoA into the mitochondrial matrix for beta oxidation.

• Malonyl CoA

  • Produced during fatty acid synthesis; serves as an allosteric inhibitor of carnitine acyltransferase I.

  • High levels of malonyl CoA inhibit transport of fatty acyl CoA into the matrix, thus favoring lipid synthesis over oxidation.

Beta Oxidation Regulation

• Beta Hydroxyacyl CoA Dehydrogenase

  • Inhibited by high ratios of NADH/NAD⁺ and acetyl CoA, indicating a high energy state.

Acetyl CoA Carboxylase (ACC)

• ACC Function

  • Enzyme that converts acetyl CoA to malonyl CoA, crucial for fatty acid synthesis.

  • Active when dephosphorylated, inactive when phosphorylated.

• Phosphorylation of ACC

  • Enzyme inactivated by Protein Kinase A (PKA), which increases in response to glucagon during low blood glucose conditions.

• Consequences of Phosphorylation

  • Inhibits the formation of malonyl CoA leading to increased beta oxidation.

AMP-Activated Protein Kinase (AMPK)

• AMPK Roles

  • Acts as a central regulator of cellular energy homeostasis.

  • Activated by AMP, inhibited by ATP.

  • Activation stimulates glucose uptake, glycolysis, and fatty acid oxidation; inhibits fatty acid synthesis and cholesterol synthesis.

• ACC Regulation by AMPK

  • AMPK can phosphorylate and activate ACC in response to low energy states, promoting fatty acid oxidation over synthesis.

PPAR Family of Nuclear Receptors

• PPAR Function

  • Regulate gene expression involved in lipid metabolism through fatty acid ligands.

  • PPAR alpha and delta involved in fatty acid oxidation, PPAR gamma involved in fat synthesis and storage.

mTOR Complex Dynamics

• mTORC1

  • Promotes growth and anabolism in the presence of nutrients and growth signals; active when nutrients are available (insulin, amino acids).

  • Regulated by growth factors that inhibit TSC1/2 complex leading to increased mTORC1 activity.

• Competition between AMPK and mTOR

  • mTORC1 promotes lipid synthesis; AMPK inhibits it during energy deprivation.

Cell Signaling Pathways

• Growth Factor Signaling

  • Binding activates PI3 kinase pathway, leading to AKT activation which phosphorylates TSC2, inactivating it.

  • The result: activation of mTORC1, favoring anabolic processes (cell growth, lipid synthesis).

• Phosphoinositide Metabolism

  • PIP2 is converted to PIP3 by PI3 kinase which mediates AKT activation.

  • Role of PIP3 in cancer: mutations in P10 phosphatase leading to diseases such as Cowden syndrome.

Cell Cycle and Apoptosis Assays

• Propidium Iodide Assay

  • Measures DNA content and shifts in cell cycle phases (G1, S, G2, M).

• Annexin V Assay for Apoptosis

  • Phosphatidylserine relocation to the outer leaflet indicates apoptosis, detected by fluorescently labeled Annexin V.

• Applications and Implications in Research

  • Understanding these pathways provides insights into metabolic diseases, cancer, and therapeutic strategies.

Summary of Key Points

• Regulation of fatty acid metabolism involves complex interactions between oxidative and synthetic pathways, influenced by hormonal signals and energy status of the cell. Understanding these mechanisms could lead to targeted therapies for metabolic disorders or obesity.

DETAILED VERSION OF NOTES:

Fatty Acid Regulation of Oxidation and Synthesis

• Overview of Fatty Acid Regulation

  • Focus on the intricate balance between fatty acid oxidation (breakdown for energy) and synthesis (storage as triglycerides and incorporation into phospholipids). This balance is critical for cellular energy homeostasis and is dynamically regulated in response to nutritional status, hormonal signals, and cellular energy demands.

  • When energy resources are abundant (e.g., after a meal, high insulin), synthesis is favored for energy storage. Conversely, when energy is scarce (e.g., during fasting, high glucagon, or exercise), oxidation is promoted to generate ATP.

Fatty Acyl CoA Activation

• Fatty acyl CoA

  • Free fatty acids (FFAs) must first be activated to their coenzyme A derivatives, fatty acyl CoA, before they can enter metabolic pathways such as beta-oxidation or be incorporated into complex lipids (triglycerides, phospholipids).

  • This activation occurs primarily in the cytosol and is catalyzed by a family of enzymes called acyl-CoA synthetases (also known as fatty acyl CoA ligases). These enzymes exist in various isoforms, specific for different fatty acid chain lengths (short-, medium-, long-, and very long-chain acyl-CoA synthetases).

  • The reaction is ATP-dependent and involves the formation of a high-energy thioester bond between the fatty acid and coenzyme A:
    $\text{Fatty Acid} + \text{ATP} + \text{CoA} \rightarrow \text{Fatty Acyl CoA} + \text{AMP} + \text{PP}_{i}$

  • The pyrophosphate ($\text{PP}<em>{i}$) produced is rapidly hydrolyzed to two inorganic phosphates ($2\text{P}</em>{i}$) by inorganic pyrophosphatase, making the overall reaction highly exergonic and virtually irreversible, thus driving the activation forward.

  • Fatty acyl CoA serves as the activated substrate for both the synthesis of triglycerides and phospholipids in the endoplasmic reticulum and as the initial substrate for beta-oxidation in the mitochondria.

Carnitine Shuttle and Regulation

• Carnitine Acyltransferase I (CAT I / CPT I)

  • This enzyme is located on the outer mitochondrial membrane and serves as the primary rate-limiting step and gatekeeper for the transport of long-chain fatty acyl CoAs into the mitochondrial matrix.

  • It catalyzes the transfer of the fatty acyl group from fatty acyl CoA to L-carnitine, forming acylcarnitine. Coenzyme A is simultaneously released back into the cytosol.

  • Acylcarnitine is then transported across the inner mitochondrial membrane into the matrix by the carnitine-acylcarnitine translocase (CACT), an antiporter that exchanges acylcarnitine for free carnitine.

  • Inside the mitochondrial matrix, Carnitine Acyltransferase II (CAT II / CPT II), located on the inner face of the inner mitochondrial membrane, transfers the fatty acyl group from acylcarnitine back to mitochondrial CoA, regenerating fatty acyl CoA for beta-oxidation and releasing L-carnitine to be exported by CACT.

• Malonyl CoA

  • Malonyl CoA is a crucial intermediate produced during the initial, committed, and rate-limiting step of de novo fatty acid synthesis, catalyzed by Acetyl CoA Carboxylase (ACC).

  • Its presence signals active fatty acid synthesis and energy abundance within the cell.

  • Malonyl CoA acts as a potent allosteric inhibitor of carnitine acyltransferase I (CPT-I).

  • High levels of malonyl CoA prevent the entry of long-chain fatty acyl CoAs into the mitochondrial matrix, effectively coupling active fatty acid synthesis with the inhibition of fatty acid oxidation. This mechanism ensures that the cell avoids a futile cycle of simultaneously synthesizing and breaking down fatty acids.

Beta Oxidation Regulation

• Beta Hydroxyacyl CoA Dehydrogenase and Pathway Inhibition

  • Beta-oxidation is a cyclical pathway involving four enzymatic steps: dehydrogenation (by FAD-dependent acyl-CoA dehydrogenase), hydration, dehydrogenation (by NAD$^+$-dependent beta-hydroxyacyl CoA dehydrogenase), and thiolytic cleavage.

  • The beta-hydroxyacyl CoA dehydrogenase step is particularly sensitive to the cellular energy state.

  • It is inhibited by high cytosolic ratios of NADH/NAD$^+$ and elevated levels of acetyl CoA. A high NADH/NAD$^+$ ratio indicates an abundance of reducing equivalents, often reflecting a high energy state or active citric acid cycle/electron transport chain, thus signaling reduced need for further fatty acid breakdown.

  • High levels of acetyl CoA, the end product of beta-oxidation, can also exert feedback inhibition on the pathway. Acetyl CoA can accumulate when the citric acid cycle is saturated or if ATP demand is low (e.g., high ATP/ADP ratio), signaling that energy stores are sufficient.

  • Additionally, other enzymes in the beta-oxidation pathway are subject to product inhibition, and the overall flux is dependent on the availability of substrates (fatty acyl CoA, NAD$^+$, FAD, CoA) and the cell's energy demand.

Acetyl CoA Carboxylase (ACC)

• ACC Function

  • ACC is the rate-limiting enzyme in de novo fatty acid synthesis.

  • It catalyzes the ATP-dependent carboxylation of acetyl CoA to malonyl CoA:
    $\text{Acetyl CoA} + \text{ATP} + \text{HCO}<em>{3}^{-} \rightarrow \text{Malonyl CoA} + \text{ADP} + \text{P}</em>{i}$

  • There are two main isoforms: ACC1 (cytosolic, predominantly involved in de novo synthesis of long-chain fatty acids for storage) and ACC2 (tethered to the outer mitochondrial membrane, primarily produces malonyl CoA as an allosteric inhibitor of CPT-I, thereby regulating fatty acid oxidation).

  • ACC exists in a dynamic equilibrium between an active, dephosphorylated polymeric form and an inactive, phosphorylated depolymerized form.

• Phosphorylation of ACC

  • ACC activity is extensively regulated by phosphorylation and dephosphorylation.

  • It is inactivated by Protein Kinase A (PKA), which is activated in response to hormones like glucagon (during low blood glucose) and epinephrine (during stress or fight-or-flight response) via the cAMP signaling pathway.

  • AMP-Activated Protein Kinase (AMPK) also phosphorylates and inactivates ACC in response to low cellular energy status (high AMP:ATP ratio).

  • Conversely, insulin promotes ACC dephosphorylation and activation, primarily by activating protein phosphatases (e.g., Protein Phosphatase 2A, PP2A), which remove inhibitory phosphates from ACC, thereby stimulating fatty acid synthesis after a meal.

  • ACC is also allosterically activated by citrate (a citric acid cycle intermediate that accumulates when energy is abundant and acetyl CoA levels are high) and inhibited by long-chain fatty acyl CoAs (product inhibition).

• Consequences of Phosphorylation

  • The phosphorylation and subsequent inactivation of ACC lead to a significant decrease in the cellular concentration of malonyl CoA.

  • This reduction in malonyl CoA levels removes its allosteric inhibition on CPT-I, thereby facilitating the unimpeded transport of fatty acyl CoAs into the mitochondrial matrix.

  • The net result is increased fatty acid oxidation for energy production and a simultaneous reduction in de novo fatty acid synthesis, shifting the cell's metabolism towards fatty acid catabolism when energy is needed.

AMP-Activated Protein Kinase (AMPK)

• AMPK Roles

  • AMPK acts as a crucial central regulator of cellular energy homeostasis, often referred to as a "fuel gauge" or "master switch" of metabolism.

  • It is a heterotrimeric enzyme composed of a catalytic $\alpha$ subunit and regulatory $\beta$ and $\gamma$ subunits.

  • AMPK is activated by low cellular energy states, specifically by an increase in the AMP:ATP ratio (or ADP:ATP ratio). AMP binds to the $\gamma$ subunit, inducing a conformational change that makes the $\alpha$ subunit a better substrate for upstream kinases.

  • Upstream kinases such as LKB1 (Liver Kinase B1) and CaMKK$\beta$ (CaM-dependent protein kinase kinase $\beta$) phosphorylate a conserved threonine residue (Thr172) on the $\alpha$ subunit, leading to full activation.

  • Once activated, AMPK stimulates catabolic pathways that produce ATP (e.g., glucose uptake and glycolysis, fatty acid oxidation) and inhibits anabolic pathways that consume ATP (e.g., fatty acid synthesis, cholesterol synthesis, protein synthesis, gluconeogenesis).

• ACC Regulation by AMPK

  • A primary target of activated AMPK in fatty acid metabolism is ACC (both ACC1 and ACC2).

  • AMPK phosphorylates and inactivates ACC by phosphorylating serine residues on the enzyme, thereby reducing malonyl CoA levels.

  • This promotes fatty acid oxidation over synthesis by relieving the CPT-I inhibition, ensuring that cells prioritize energy generation from existing fatty acid stores during times of energy deprivation.

PPAR Family of Nuclear Receptors

• PPAR Function

  • The Peroxisome Proliferator-Activated Receptors (PPARs) are a family of ligand-activated transcription factors belonging to the nuclear receptor superfamily.

  • They regulate the expression of genes involved in diverse metabolic processes, including lipid metabolism, glucose homeostasis, inflammation, and cell differentiation.

  • Upon binding to their specific lipid ligands (e.g., fatty acids, eicosanoids), PPARs form heterodimers with the Retinoid X Receptor (RXR).

  • This PPAR-RXR complex then binds to specific DNA sequences called Peroxisome Proliferator Response Elements (PPREs) in the promoter regions of target genes, leading to increased or decreased gene transcription.

  • There are three main isoforms: PPAR$\alpha$, PPAR$\delta$ (or PPAR$\beta$), and PPAR$\gamma$.

  • PPAR$\alpha$ is highly expressed in tissues with high fatty acid catabolism, such as liver, heart, skeletal muscle, and kidney. It activates genes involved in fatty acid uptake, mitochondrial and peroxisomal $\beta$-oxidation (e.g., CPT-I, acyl-CoA oxidases), and lipoprotein metabolism (e.g., LPL). Fibrates (drugs used to lower triglycerides) are synthetic activators of PPAR$\alpha$.

  • PPAR$\delta$ (or PPAR$\beta$) is ubiquitously expressed and plays roles in fatty acid catabolism in various tissues, mitochondrial biogenesis, and adaptation to exercise.

  • PPAR$\gamma$ is primarily expressed in adipose tissue (responsible for adipogenesis and lipid storage) and macrophages. It regulates genes involved in adipocyte differentiation, insulin sensitivity, and lipid uptake/storage (e.g., LPL, CD36, aP2). Thiazolidinediones (TZDs), a class of anti-diabetic drugs, are synthetic activators of PPAR$\gamma$.

mTOR Complex Dynamics

• mTORC1

  • The mechanistic Target of Rapamycin (mTOR) is a serine/threonine kinase that forms two distinct multiprotein complexes: mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2). The provided context focuses on mTORC1.

  • mTORC1 acts as a central hub that integrates signals from nutrients (amino acids, glucose, lipids), growth factors (insulin, IGF-1), and energy status to promote anabolism (cell growth, proliferation, protein synthesis, lipid synthesis) and inhibit catabolism.

  • mTORC1 is active when nutrients are abundant and growth signals are present. It contains mTOR, Raptor (regulatory-associated protein of mTOR), mLST8, PRAS40, and Deptor.

  • mTORC1 activity is positively regulated by growth factors through the PI3K/AKT pathway (see below) which inhibits the TSC1/TSC2 complex.

  • The TSC1/TSC2 complex acts as a GTPase-activating protein (GAP) for the small GTPase Rheb. When TSC1/2 is active, it converts Rheb-GTP to Rheb-GDP, preventing Rheb from activating mTORC1. When TSC1/2 is inhibited (e.g., by AKT), Rheb remains in its active Rheb-GTP state, thereby activating mTORC1.

  • mTORC1 activation leads to the phosphorylation of downstream targets such as S6 Kinase (S6K) and Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), promoting protein synthesis. It also promotes lipid and cholesterol synthesis by activating SREBP-1c and inhibits autophagy.

• Competition between AMPK and mTOR

  • AMPK and mTORC1 operate in an antagonistic manner to maintain cellular energy balance.

  • When energy is high, mTORC1 promotes anabolic processes including protein, lipid, and nucleotide synthesis.

  • When energy is low and AMP levels rise, AMPK becomes activated. Activated AMPK directly phosphorylates and inhibits mTORC1 components (e.g., Raptor) and also activates the TSC1/TSC2 complex, thereby inhibiting Rheb and leading to the deactivation of mTORC1.

  • This reciprocal regulation ensures that anabolic processes are suppressed during energy deprivation while catabolic pathways are favored.

Cell Signaling Pathways

• Growth Factor Signaling (PI3K/AKT Pathway)

  • Growth factors (e.g., insulin, IGF-1) bind to and activate receptor tyrosine kinases (RTKs) on the cell surface. This leads to autophosphorylation of the RTK, creating docking sites for adaptor proteins.

  • Phosphoinositide 3-Kinase (PI3K) is recruited and activated, phosphorylating phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3) at the inner leaflet of the plasma membrane.

  • PIP3 serves as a secondary messenger and a docking site for proteins containing pleckstrin homology (PH) domains, including AKT (Protein Kinase B) and PDK1.

  • AKT is recruited to the membrane by PIP3 and subsequently activated by phosphorylation at two key sites: Thr308 by PDK1 and Ser473 by mTORC2.

  • Activated AKT phosphorylates numerous downstream targets, including TSC2 (a component of the TSC1/2 complex). Phosphorylation of TSC2 inactivates the TSC1/2 complex, leading to sustained Rheb-GTP levels and the activation of mTORC1.

  • This pathway is critical for promoting anabolic processes like cell growth, proliferation, survival, and lipid synthesis in response to growth signals and nutrient availability.

• Phosphoinositide Metabolism and PTEN

  • PIP2 ($PI(4,5)P<em>{2}$) and PIP3 ($PI(3,4,5)P</em>{3}$) are key signaling lipids in the cell membrane.

  • The precise regulation of PIP3 levels is vital for cell signaling. PTEN (Phosphatase and Tensin Homolog) is a lipid phosphatase that plays a critical role by dephosphorylating PIP3 back to PIP2, thus acting as a negative regulator of the PI3K/AKT pathway.

  • Role of PTEN in Cancer and Disease: PTEN is a well-known tumor suppressor. Mutations or deletions in the PTEN gene lead to constitutive activation of the PI3K/AKT pathway, promoting uncontrolled cell growth and survival, which contributes to various cancers. PTEN mutations are also associated with syndromes like Cowden syndrome, characterized by benign and malignant tumors.

Cell Cycle and Apoptosis Assays

• Propidium Iodide (PI) Assay for Cell Cycle Analysis

  • The PI assay is a widely used flow cytometry method to measure cellular DNA content, allowing for the quantification of cells in different phases of the cell cycle (G1, S, G2, M).

  • Propidium Iodide is a fluorescent intercalating agent that binds stoichiometrically to double-stranded DNA. After permeabilization of the cell membrane, PI enters the cell and binds to DNA.

  • Cells in the G1 phase (before DNA replication) have a diploid amount of DNA (2n chromosome number) and thus bind a specific amount of PI, resulting in a distinct fluorescence intensity peak.

  • Cells in the S phase (DNA synthesis) have varying amounts of DNA between 2n and 4n, appearing as a broad distribution of fluorescence intensities.

  • Cells in the G2/M phases (after DNA replication, before cell division) have twice the DNA content of G1 cells (4n chromosome number) and exhibit a fluorescence intensity peak twice as high as the G1 peak.

  • Apoptotic or necrotic cells often appear as a "sub-G1" peak with very low DNA content due to DNA fragmentation and leakage.

  • This assay is crucial for studying cell proliferation, DNA damage responses, and the effects of various experimental treatments.

• Annexin V Assay for Apoptosis

  • The Annexin V assay is used to detect and quantify cells undergoing apoptosis (programmed cell death).

  • A key early event in apoptosis is the translocation of phosphatidylserine (PS) from the inner leaflet of the plasma membrane to the outer leaflet, where it becomes exposed to the extracellular environment.

  • Annexin V is a calcium-dependent protein that has a high affinity for phosphatidylserine. It is typically conjugated to a fluorescent marker (e.g., FITC, APC, PE) for detection.

  • When cells are stained with fluorescently labeled Annexin V, early apoptotic cells will bind Annexin V on their surface but will still have an intact cell membrane (excluding vital dyes).

  • The assay is often combined with a vital dye like Propidium Iodide (PI) or 7-aminoactinomycin D (7-AAD).

  • Annexin V-positive, PI-negative cells are considered early apoptotic (PS exposed, membrane intact).

  • Annexin V-positive, PI-positive cells are considered late apoptotic or necrotic (PS exposed, membrane compromised).

  • Annexin V-negative, PI-negative cells are viable/healthy.

  • This combination allows for a clear distinction between viable, early apoptotic, late apoptotic, and necrotic cell populations.

• Applications and Implications in Research

  • Understanding these intricate signaling pathways and metabolic regulation mechanisms provides fundamental insights into health and disease.

  • These pathways are highly relevant to the study and treatment of metabolic diseases (e.g., obesity, type 2 diabetes, fatty liver disease), cardiovascular diseases, and various cancers.

  • Targeted therapies for these conditions can be developed by manipulating specific components of these pathways, for example, by activating AMPK or PPARs, or inhibiting mTORC1 or the PI3K/AKT pathway.

Summary of Key Points

• The regulation of fatty acid metabolism is a complex, multi-tiered process involving hormonal signals (insulin, glucagon), cellular energy status (AMPK, ATP/AMP ratio), transcriptional control (PPARs), enzymatic activities (ACC, CPT-I, beta-oxidation enzymes), and intricate cell signaling networks (mTOR, PI3K/AKT).

• This dynamic interplay ensures that cells precisely balance fatty acid oxidation and synthesis to meet energy demands, store excess energy, and maintain cellular homeostasis.

• Dysregulation in any of these mechanisms can lead to significant metabolic disorders, highlighting their importance as therapeutic targets.